NextCure, Inc. 8-K

What Happened NextCure announced interim Phase 1 dose-escalation data for its investigational drug SIM0505 at ASCO 2026 (poster presented June 1, 2026) and updated its corporate presentation. The data (data cutoff April 7, 2026) come from 59 patients in a first‑in‑human global study (U.S. n=25; China n=34) dosed 1.6–9.6 mg/kg, enrolled without preselection for CDH6 expression. The company also stated its cash, cash equivalents and marketable securities are expected to fund planned operations into the first quarter of 2027.

Key Details

• Study population/data cutoff: 59 advanced solid‑tumor patients, data cut April 7, 2026.
• Gynecologic efficacy (patients in 4.8–8.0 mg/kg cohorts with ≥12 weeks follow‑up, n=20): overall ORR 55% (11/20); ovarian cancer 52.9% (9/17; one unconfirmed PR and one PR pending confirmation); uterine serous carcinoma 66.7% (2/3).
• Safety: TEAEs mostly hematologic, nausea/vomiting; Grade 3–4 events predominantly hematologic and described as manageable without primary hematologic prophylaxis. TRAEs causing discontinuation: 3 events (Grade 2 ILD and Grade 3 fungal pneumonia at 6.4 mg/kg; Grade 4 thrombocytopenia at 9.6 mg/kg). AESIs included pneumonitis (Grade 1 at 5.6 mg/kg) and ILD (Grade 2 at 6.4 mg/kg).
• Demographics snapshot: median age 58; 96.6% female; 57.6% Asian; tumor types: ovarian 78%, USC/other endometrial 16.9%, RCC 5.1%.
• Corporate actions: press release, ASCO poster, and updated corporate presentation were furnished with the 8‑K; company will engage investors referencing these materials.

Why It Matters The ASCO poster shows early, measurable anti‑tumor activity of SIM0505 in a small set of gynecologic cancer patients, which may inform dose selection and next steps in development. Safety signals are chiefly hematologic but included a few serious events at higher doses, which will be important for assessing tolerability and dose optimization. Separately, the company’s stated cash runway into Q1 2027 gives investors a near‑term timeline for financing needs; the company notes this estimate is based on assumptions that could change.